Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 14/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | PAK3 | O75914 | 2/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.40 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312132 | 0.90 | NTRK1 (0.47) | NTRK1JAK2JAK3IGF1RPAK3 | |
| SCHEMBL10312185 | 0.90 | NTRK1 (0.47) | NTRK1JAK2JAK3IGF1RPAK3 | |
| SCHEMBL10312218 | 0.87 | NTRK1 (0.44) | NTRK1JAK2JAK3PAK1 | |
| SCHEMBL10312102 | 0.86 | GRK6 (0.39) | NTRK1JAK2JAK3 | |
| SCHEMBL10312211 | 0.85 | IGF1R (0.50) | NTRK1JAK2IGF1R | |
| SCHEMBL10312083 | 0.81 | IGF1R (0.43) | NTRK1JAK2IGF1R | |
| SCHEMBL10312082 | 0.80 | HRH4 (0.44) | IGF1RPAK1 | |
| SCHEMBL10312212 | 0.79 | IGF1R (0.54) | NTRK1JAK2IGF1R | |
| SCHEMBL10312087 | 0.78 | IGF1R (0.43) | IGF1R | |
| SCHEMBL10312197 | 0.77 | NTRK1 (0.42) | NTRK1JAK2JAK3IGF1RPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | NTRK1 482/4885JAK2 176/4885JAK3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.